We have located links that may give you full text access.
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
Journal of the National Cancer Institute 2019 March 20
We retrospectively assessed association of stromal tumor-infiltrating lymphocytes (sTILs) with clinical outcomes and molecular variables reportedly predictive of trastuzumab-benefit in NSABP B-31 (N = 2,130). sTILs were assessed in 1,581 eligible B-31 cases utilizing all available H&E slides. Mean concordance between main reviewer and six other pathologists was 90.8% in 100 cases. Cox regressions were used to calculate hazard ratios (HRs). In chemotherapy and trastuzumab-added-to-chemotherapy arms, increases in sTILs, as a semi-continuous variable (combined arms HR = 0.42, 95% [CI]=0.27 to 0.64, two-sided P < 0.001) or as lymphocyte-predominant breast cancer (BC) with >50% sTILs (combined arms HR = 0.65, 95% CI = 0.49-0.86, two-sided P = 0.003), were statistically significantly associated with improved disease-free survival. There was no association of sTILs with trastuzumab-benefit. However, higher sTILs were statistically significantly associated with higher-trastuzumab-benefit groups by 8-gene prediction model (two-sided P < 0.001). Neither PIK3CA mutations nor Fc-gamma-receptor polymorphisms were associated with sTILs. sTILs may have utility as a prognostic biomarker identifying HER2-positive early-BC at low recurrence risk.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app